Strata Critical Medical (SRTA) EBITDA (2019 - 2026)

Strata Critical Medical has disclosed EBITDA across 8 years of filings, most recently posting -$3.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 47.69% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$20.0 million (up 35.27% YoY), while the FY2025 annual figure was -$22.4 million, up 0.76% from the prior year.
• EBITDA improved to -$3.0 million in Q1 2026, from -$6.4 million in the prior quarter.
• Over the last five years, EBITDA for SRTA reached as high as -$3.0 million in Q1 2026 and fell as low as -$35.6 million in Q4 2023.
• The 5-year median for EBITDA is -$7.4 million (2023), against an average of -$10.1 million.
• Annual changes were most pronounced in 2022 — EBITDA sank 224.02% — and 2024, when it surged 83.43%.
• A 5-year view of EBITDA shows it stood at -$9.7 million in 2022, then tumbled by 266.11% to -$35.6 million in 2023, then surged by 83.43% to -$5.9 million in 2024, then slipped by 8.49% to -$6.4 million in 2025, then soared by 53.57% to -$3.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.0 million, -$6.4 million, and -$5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.